Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 501–600 of 1,871
New kidneys, old risks: cardiovascular challenges after transplantation
Craenenbroeck, A. H. V., Chinnappa, S., Dounousi, E. C., Fernández‐Fernández, B., Iatridi, F., Mark, P. B., Piko, N., Stegbauer, J., Torino, C., Vogt, L., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf239 · Cited by 13
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Abdelhamid, M., Abdrabou, M. M., Faris, E., Elkaffas, S. M. H., Hosny, M., & Hassan, A. (2025) · Cardiac failure review · doi:10.15420/cfr.2025.17 · Cited by 12
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Nicola, L. D., Cupisti, A., D’Alessandro, C., Gesualdo, L., Santoro, D., & Bellizzi, V. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02135-y · Cited by 10
Jia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Azagury, D. E., Alimi, Y., & Prindeze, N. J. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12086-5 · Cited by 13
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Ndumele, C. E., Biering‐Sørensen, T., Matsushita, K., Selvin, E., Coresh, J., Shah, A. M., Solomon, S. D., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.077894 · Cited by 15
Upadhyay, A., & Haider, L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0036 · Cited by 6
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“13 Data in individuals with overweight or obesity but without diabetes, including the landmark SELECT trial, further support cardioprotective effects independent of glucose-lowering.”
Glucagon-like peptide-1 receptor agonists and aspiration risk
McIsaac, D. I., & Bryson, G. L. (2024) · BMJ · doi:10.1136/bmj.q1986 · Cited by 8
Alsalloum, M. A., Albekery, M. A., & Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630160 · Cited by 12
We Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases
Ferreira, J. P., & Zannad, F. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.025 · Cited by 7
Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment
Edwards, N. C., Pavlovic, D., Ferro, C. J., & Townend, J. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01234-y · Cited by 8
“GLP1R agonists reduce the risk of major cardiovascular events and all-cause death in patients with CKD, and reduce the progression of kidney dysfunction in patients with CKD and diabetes 195 .”
InfluentialAl-Dahi, W. A., Alenezi, A., Alessa, T., Alhamdan, R., Al-Humood, K., Alqallaf, A., AlOtaibi, T. M., AlRajab, H., Alshammari, A. M., Alyousef, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01838-0 · Cited by 9
“It addresses a critical need for adults with T2D living with the common comorbidity of CKD [77].”
Measurement, Estimation, and Correlates of the GFR before and after Bariatric Surgery
Friedman, A. N., Chang, A. R., Chuah, L. L., Favrè, G., Grangeon-Chapon, C., Lane, K. A., Li, Y., le Roux, C. W., Lieske, J. C., Morales, E., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000797 · Cited by 8
Wright, E. E., Cuenca, A. M. C., & Ngui, D. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.005 · Cited by 6
Brown, J. M., & Huck, D. M. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102299 · Cited by 6
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
“Multiple phase 2 and 3 trials support the use of incretin drugs in chronic kidney disease (CKD) [14], osteoarthritis [15], obstructive sleep apnea (OSA) [16] and even in early Parkinson’s disease [17], demonstrating the pleiotropic benefits of these agents in preventing chronic disease progression…”
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
“37 .”
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 18
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Diabetes and Glucose Management in People on Hemodialysis
Agarwal, S., Mader, J. K., Arevalo, G., Avula, S., Chavez, E., Sloan, L. A., & Galindo, R. J. (2025) · Diabetes Spectrum · doi:10.2337/dsi24-0015 · Cited by 7
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Wang, X., Wang, W., Han, M., Zhang, J., & Li, Y. (2025) · Transplant Immunology · doi:10.1016/j.trim.2025.102280 · Cited by 10
Protein restriction in CKD: an outdated strategy in the modern era
Bawazir, A., Topf, J. M., & Hiremath, S. S. (2025) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-po03en · Cited by 7
Wang, J., Lin, C., Cai, X., Wang, Y., Wei, T., Wang, Y., Tie, C., Yang, Y., Lv, F., Yang, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16552 · Cited by 7
GLP-1 receptor agonists for kidney transplant recipients
Schmitz, S. H., & Orandi, B. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf199 · Cited by 9
Mohamed, A. A., Al-Saffar, A., Mohamed, A. A., Khamis, M. H., Khalaf, A. A., Alaradi, H., Abuhamaid, A. I., Sanad, A. H., Abbas, H. L., Abdulla, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.71739 · Cited by 8
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
The management of chronic kidney disease not requiring renal replacement therapy in general practice
Kiel, S., Negnal, M., Stracke, S., Fleig, S. V., Kuhlmann, M. K., & Chenot, J. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0230 · Cited by 7
Ashraf, T., Bai, S., Kumar, A., Sagar, R. S., Saloni, F., Kumar, A., Kumar, R., Pahwani, A., Kumar, V., Hassaan, M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003126 · Cited by 7
Lan, N. S. R., McFadden, B., Johnson, A. R., Shedden, P., Fegan, P. G., Puttagunta, H., Ho, S., Gillett, R., Swaminathan, R., & Dwivedi, G. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.007 · Cited by 8
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 12
Sebhat, I. K., Murphy, M. J. M., Zheng, S., Lovelett, R. J., Engelstoft, M. S., Kosinski, D., Yang, X., Dunn, V., Whang, J., Lombardo, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.001 · Cited by 9
Changing the paradigm in heart failure: shifting from treatment to prevention
Chang, A. J., Liang, Y., Girouard, M. P., Bhatt, A. S., Sandhu, A. T., Sauer, A. J., Greene, S. J., Harrington, J., Go, A. S., & Ambrosy, A. P. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10454-2 · Cited by 10
Li, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 11
“Their efficacy in slowing CKD progression and reducing hard cardiorenal outcomes has been consistently demonstrated in large cardiovascular outcome trials and dedicated renal studies, including CREDENCE, DAPA-CKD, and FLOW [82, 83, 85, 86].”
Lin, R., Hsu, C., Shih, M., Chien, K., & Wu, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70224 · Cited by 13
“36, 40, 42, 43 These”
Wang, L., Wang, J., Wu, W., Xue, X., He, T., Lv, S., Wu, W., Sun, Q., Zhou, Q., Zhang, S., et al. (2025) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-25-00031 · Cited by 7
Rico-Fontalvo, J. E., Ciudin, A., Correa‐Rotter, R., Diaz-Crespo, F. J., Bonanno, C., Lecube, A., Daza-Arnedo, R., Morales, E., Quiroga, B., Lorca, E., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.06.013 · Cited by 11
Yao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
“Similarly, four studies from the FLOW trial were included because they each reported different outcomes of interest [30, 31, 34, 35].”
InfluentialInflammation: A Key Driver in the Progression of CKD
Stenvinkel, P. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.06.002 · Cited by 8
Glomerular pressure and tubular oxygen supply: a critical dual target for renal protection
Masuda, T., & Nagata, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01944-9 · Cited by 7
“The recent FLOW trial, a randomized controlled trial of participants with type 2 diabetes and CKD, demonstrated that the GLP-1R agonist semaglutide reduced the risk of clinically important kidney outcomes, major cardiovascular events, and death of any cause [56].”
Zhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 7
“…in a press release which reported that allocation to semaglutide, compared with placebo, led to a 24% reduction in the primary composite outcome of kidney disease progression, major cardiovascular events or all-cause mortality in 3533 patients with CKD, albuminuria, and type 2 diabetes [21 , 22 ].”
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 11
de Moraes, T. P., Moura, A. F., Sposito, A. C., Lopes, F. P. P. L., QUADROS, A. R. D. A., Gadelha, V., Eliaschewitz, F. G., Bertoluci, M. C., Samaan, F., Montenegro, C., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0231en · Cited by 8
“…therapy (GDMT), once limited to pharmacological blockade of the renin-angiotensin-aldosterone system 1 , have expanded to include sodium-glucose cotransporter (SGLT2) inhibitors 2–4 , nonsteroidal mineralocorticoid receptor antagonists 5 , and glucagon-like peptide-1 (GLP-1) receptor agonists 6 .”
Exploring the Effects of Tirzepatide on Obstructive Sleep Apnea: A Literature Review
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, D., Akhtar, M., Razick, A. A., & Frezza, E. (2025) · Cureus · doi:10.7759/cureus.80164 · Cited by 9
“The recent FLOW trial using semaglutide in patients with chronic kidney disease found significant decreases in composite major kidney disease events (HR 0.76, 95% CI: 0.66-0.88, p= 0.0003) [74].”
InfluentialUyaroğlu, O. A., Ruža, I., Škrha, J., Patoulias, D., Bevc, S., Bojadjiev, B. I., Gómez‐Huelgas, R., Bojunga, J., Leśniak, W., Carretero‐Gómez, J., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.11.018 · Cited by 8
The immunology of exercise: Mechanisms, mediators, and therapeutic opportunities
Phelps, C. M., & Meisel, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.04.016 · Cited by 14
Harnessing Evolution and Biomimetics to Enhance Planetary Health: Kidney Insights
Stenvinkel, P., Shiels, P. G., Kotanko, P., Evenepoel, P., & Johnson, R. J. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000582 · Cited by 7
Cao, W., Cao, G., Meng, Q., Li, D., Zhang, J., Wu, T., & Zhang, F. (2026) · The FASEB Journal · doi:10.1096/fj.202504735r · Cited by 9
“Similarly, the glucagon-like peptide-1 receptor (GLP-1RA) agonist semaglutide, a novel glucose-lowering agent, not only improves glycemic control but also attenuates eGFR decline in clinical studies, potentially by stimulating mitochondrial biogenesis and maintaining energy homeostasis [123, 124].”
Vaduganathan, M., Green, J. B., Heerspink, H. J. L., Kim, S. G., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Rossing, P. R., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf160 · Cited by 14
Self-citationCardio-Renal Syndrome: Review and New Perspectives
Martín, M., Fernández, M., Bacigalupe, L. P., & Rozado, J. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010004 · Cited by 7
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“…Lowers blood pressure and lipid levels [50] Lowers kidney disease risk, slows eGFR decline, improves albuminuria, reduces CV events and mortality [16] Improves osteoarthritic pain and function [23] Reduces liver fat content [48] Reduces all-cause mortality [16] ~15% by week 68 [19] GLP-1…”
InfluentialPharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Fong, J. M. N., Sia, C., & See, K. C. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-012 · Cited by 5
“[5] Historically, CKD was considered a non‑traditional cardiovascular risk factor [6] and omitted from major coronary risk scores.”
Zelada, H., Campana, M., Kawai, K., Redden, D. T., Agarwal, G., Gutiérrez, O. M., & Kumar, V. (2025) · Clinical Transplantation · doi:10.1111/ctr.70144 · Cited by 6
“In non-transplanted Chronic Kidney Disease patients with type 2 diabetes, a large randomized controlled trial demonstrated a slowing of renal function decline, a reduction in the initiation of dialysis, and a decrease in cardiovascular-related mortality [14].”
Fetzner, J., & Rafi, E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae817 · Cited by 6
Rethinking Models of Chronic Kidney Disease Care: A Narrative Review
Wallace, H., Daly, J. O., Jun, M., & Nelson, C. (2025) · Kidney & Blood Pressure Research · doi:10.1159/000546562 · Cited by 6
Prognosis After >50% Decline in eGFR in Heart Failure Patients
Zahir, D., Elmegaard, M., Garred, C. H., Nouhravesh, N., Fosbøl, E. L., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.027 · Cited by 5
Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis
Stefanou, M., Tentolouris, A., Panagiotopoulos, E., Theodorou, A., Mengel, A., Athanasaki, A., Lambadiari, V., Peppa, Μ., Papadopoulou, Μ., Παρασκευάς, Γ. Π., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109271 · Cited by 6
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare
Dayer, V. W., Nourhussein, I., Kasle, A., Hansen, R. N., Navas, A., & Sullivan, S. D. (2025) · Value in Health · doi:10.1016/j.jval.2025.07.007 · Cited by 7
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
Pladevall, M., ZIEMIECKI, R. M., Johannes, C. B., Khan, A. M., Mines, D. I., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García‐Sempere, A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01717-8 · Cited by 8
“…of a primary composite kidney outcome (kidney failure onset, at least a 50% reduction in estimated glomerular filtra‑ tion rate [eGFR] from baseline, or death from kidney‑related or cardiovascular causes) when comparing patients initiating semaglutide with patients initiating placebo [15, 16].”
Biglari, S., Mischak, H., Beige, J., Latosińska, A., Siwy, J., & Banasik, M. (2025) · Biomolecules · doi:10.3390/biom15060809 · Cited by 10
Shi, C., Wang, X., Qin, S., He, A., Wu, X., Ke, Q., Shen, R., Wan, Y., Wang, L., Xiao, Y., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06519-y · Cited by 7
Chen, Y., Shan, Y., Wang, T., Liu, Z., Zhao, Z., & He, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s537001 · Cited by 11
“24 Notably, SBP and DBP showed a trend toward reduction, though without statistical significance.”
Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges
Lees, J. S., Škoberne, A., Zhang, L., Wyatt, C., Fabian, J., Wang, A. Y.-M., Oni, L., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00653-7 · Cited by 6
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
Hansrivijit, P., Ortega-Montiel, J., Wexler, D. J., Patorno, E., & Paik, J. M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101013 · Cited by 6
“19 Whether these kidney protection and mortality benefits extend to patients who are prescribed tirzepatide or those with CKD without T2D is not fully known.”
Morello, C. M., Awdishu, L., Lam, S., Heman, A., & Bounthavong, M. (2024) · Kidney360 · doi:10.34067/kid.0000000597 · Cited by 7
Datla, S., Albar, Z., Eaton, E., Porges, J., Nennstiel, M., Sullivan, C., Greene, L. A., Al-Kindi, S. G., Montgomery, E. A., Padiyar, A., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101004 · Cited by 7
“The FLOW trial (Effects of Semaglutide on Chronic Kidney Disease in Patients with T2DM) demonstrated significantly reduced risk of major kidney disease events as well as reduced risk of major adverse cardiovascular events and death in those who received semaglutide [15].”
Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic
Mashayekhi, M., Zuckerman, J. E., Koubar, S. H., Wu, J., Qing, J., Abdipour, A., Lerma, E. V., Peters, W. R., & Norouzi, S. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02804-7 · Cited by 8
“In the FLOW trial, semaglutide caused a 24% relative risk reduction in the composite outcome of kidney failure, eGFR decline ≥ 50%, or kidney-related death (HR 0.76; 95% CI: 0.66–0.88) [57, 58].”
InfluentialObesity as a modifiable risk factor in patients with chronic kidney disease
Morales, E., Jenssen, T. G., Bevc, S., Miglinas, M., Martin, W. P., Theodorakopoulou, M. P., Jørgensen, M. B., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf231 · Cited by 10
Meier, M., Cummings, J. L., Abdelsaid, M. A., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101282 · Cited by 7
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Jansz, T. T., Young, K., Hopkins, R., McGovern, A. P., Shields, B. M., Hattersley, A. T., Jones, A. G., Pearson, E. R., Bingham, C., Oram, R. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06577-2 · Cited by 5
Soe, K. K., & Selvarajah, D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101149 · Cited by 6
“85 Novel nonsteroidal mineralocorticoid receptor antagonists, including finerenone and esaxerenone, are shown to provide reductions in albuminuria with a lower risk of hyperkalemia.”
Mulvagh, S. L., Inzucchi, S. E., Marx, N., Poulter, N. R., Deanfield, J. E., Pop‐Busui, R., Emerson, S. S., Mann, J. F. E., Engelmann, M. D. M., Hovingh, G. K., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0245 · Cited by 6
Self-citationSchechter, M., Fishkin, A., Mosenzon, O., Sehtman-Shachar, D. R., Cukierman‐Yaffe, T., Leibowitz, G., & Aharon‐Hananel, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02962-8 · Cited by 10
“Instead, they may reflect a broader indirect therapeutic effects of GLP-1 RAs on glycemic control, body weight, blood pressure, albuminuria, and systemic inflammation [35, 42–44].”
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Sánchez-Baya, M., Bolufer, M., Vázquez, F., Alonso, N., Massó, E., Paúl, J., Coll-Brito, V., Taco, O., Antón-Pàmpols, P., Gelpi, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041048 · Cited by 6
“GLP-1RA drugs improve glycemic control, reduce weight and cardiovascular risk and increase survival rates in patients with T2DM [75], reducing major adverse cardiac events, lowering all-cause mortality and minimizing hospitalizations due to heart failure [75–78].”
InfluentialSharma, P., Buddhavarapu, V. S., Dhillon, G. S., Verma, R. K., Devadoss, R., Raynor, J., Munjal, R. S., Grewal, H., & Kashyap, R. (2024) · Endocrines · doi:10.3390/endocrines5030023 · Cited by 8
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
Joo, J. H., Zhao, A., Chalasani, M., Allan, K. C., & Rachitskaya, A. V. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.12.014 · Cited by 6
Glucagon-like Peptide-1 Receptor Agonist Use in Hospital: A Multicentre Observational Study
Ray, P., Moggridge, J. A., Weisman, A., Tadrous, M., Drucker, D. J., Perkins, B. A., & Fralick, M. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.10.011 · Cited by 5
Semaglutide and diabetic retinopathy: an OHDSI network study
Cai, C. X., Nishimura, A., Baxter, S. L., Goetz, K., Hribar, M. R., Toy, B. C., Barkmeier, A. J., Wang, S. Y., Swaminathan, S. S., Flowers, A. M., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005424 · Cited by 12
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
“The FLOW trial not only con fi rmed the improvement of kidney outcomes with semaglutide in patients with concomitant CKD and DM, but also demonstrated clinically signi fi cant reductions in death from CV causes as well as in the risk of major CV events [243].”
Trends in nephrology: from “diabetic kidney disease” to “CKD with risk factor diabetes”
Speeckaert, M. M., & Rossing, P. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf134 · Cited by 7
Self-citationTrenas, A., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., Gómez‐Doblas, J. J., Martínez-Esteban, M. D., Bouarich, O., García‐Casares, N., Fernández‐García, D., de Lucas, M.-D. G., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.007 · Cited by 6
Aoyama, K., Okada, A., Kaneko, H., Azegami, T., Suzuki, Y., Meguro, S., Fujiu, K., Takeda, N., Morita, H., Node, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70255 · Cited by 6
“…2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated not only glycaemic benefits but also cardiovascular 2 – 10 and renal protective effects 11 – 14 in large-scale clinical trials, leading to their prioritised use in recent treatment guidelines.”
Schooling, C. M., Yang, G., Soliman, G. A., & Leung, G. M. (2025) · Life · doi:10.3390/life15020253 · Cited by 9
“…reduces the risk of prostate cancer [2] and ameliorates major kidney disease events (kidney failure onset, reduction in estimated glomerular filtration rate of 50% or more, or death from kidney-related or cardiovascular causes) in people with both chronic kidney disease and type 2 diabetes [23].”
Bae, J. H., & Cho, Y. M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14336 · Cited by 5
Aroda, V. R., Buzzetti, R., Dalskov, S., Jain, A. B., Larsen, J. S., Mathieu, C., Pratley, R. E., Videmark, A. N., Watt, T., & Buse, J. B. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00126-9 · Cited by 10
Self-citationLow Energy Diets for Obesity and CKD (SLOW-CKD Randomized Feasibility Study)
Conley, M. M., Mayr, H. L., Hepburn, K. S., Holland, J. J., Mudge, D. W., Tonges, T. J., Modderman, R. S., Gerzina, S. A., Johnson, D. W., Viecelli, A. K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.021 · Cited by 7
“13,14 14-16 However, these medications have side effects, recurring high costs, 17 and global shortages are impacting continuity of care.”
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
“59 Similarly, the SELECT trial in obese patients with cardiovascular disease found that semaglutide significantly reduced eGFR decline and slowed CKD progression, effects that appeared independent of weight loss.”
From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome
Re, C. L., Kim, J., & Fornoni, A. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-07046-z · Cited by 5
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan
Fang, C., Norouzi, S., & Garimella, P. S. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001101 · Cited by 6
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.